[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cushing-s-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cushing-s-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100535017","phase-2-evaluating-the-functional-status-of-the-adrenal-glands-with-68gaga-pentixafor-in-hyperaldosteronism-and-hypercortisolism-100535017",false,"NCT06246357","Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism","Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism","* INCLUSION CRITERIA:\n* Must have any of the following:\n\n  * one or more adrenal masses on CT and\u002For MRI and biochemical evidence of excess aldosterone\n\nOR\n\n--ACTH-independent hypercortisolism, with or without adrenal masses on CT and\u002For MRI\n\nOR\n\n* history of ACTH-dependent hypercortisolism (with or without adrenal enlargement)\n* Co-enrollment in 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial.\n* Age \\>=18 years.\n* ECOG performance status \\\u003C= 2.\n* Women of child-bearing potential (WOCBP) and men must agree to use an effective contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) for two weeks prior to \\[68Ga\\]Ga-PentixaFor scan and for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n\n  * Breastfeeding should be discontinued for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n  * Men must agree not to donate sperm for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n* Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening.\n* Uncontrolled intercurrent illness or social situations based on the review of medical history that would limit compliance with study requirements.\n* Contraindications to having an MRI and CT.","ALL","18 Years","120 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nThe adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional.\n\nObjective:\n\nTo see if a new radioactive tracer (\\[68Ga\\]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans.\n\nEligibility:\n\nPeople aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242).\n\nDesign:\n\nParticipants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed.\n\nParticipants will have one PET scan with the study tracer.\n\nThe tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes.\n\nParticipants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan.\n\nParticipants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.",[27,28,29],"Hyperaldosteronism","Hypercortisolism","Cushing s Syndrome",[31,32],"Adenomas","PET Imaging","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2024-09-23",{"date":41,"type":21},"2028-04-01",{"name":43,"class":44},"National Cancer Institute (NCI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100619906","phase-1-diagnostic-value-of-cxcr4-targeted-petct-in-acth-dependent-and-independent-cushings-syndrome-100619906","NCT07350707","Diagnostic Value of CXCR4-targeted PET\u002FCT in ACTH-dependent and Independent Cushing's Syndrome","CXCR4-Targeted PET Imaging for the Differential Diagnosis of ACTH-Dependent and ACTH-Independent Cushing's Syndrome: A Prospective Observational Study","Inclusion Criteria:\n\n* Clinical suspicion or confirmed diagnosis of Cushing's syndrome, based on clinical features (e.g., central obesity, moon face, muscle weakness) and\u002For abnormal cortisol-related biochemical tests.\n* Able and willing to undergo PET\u002FCT imaging with both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE.\n* Willing to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Prior administration of therapeutic or investigational radiopharmaceuticals within 5 physical half-lives before study imaging.\n\nPregnancy or breastfeeding.\n\n* History of allergic reaction to gallium-based tracers or related compounds.\n* Clinically unstable condition or severe organ dysfunction that, in the investigator's opinion, would interfere with PET\u002FCT imaging or study participation.\n* Inability to complete both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE PET\u002FCT imaging due to clinical or logistical reasons.","10 Years","80 Years",{"count":56,"type":21},160,[58,24],"PHASE1","In previous clinical practice, 68Ga-Pentixafor PET\u002FCT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms. Building on this, and leveraging the Nuclear Medicine expertise at Peking Union Medical College Hospital, we aim to conduct a prospective observational study investigating the role of CXCR4-targeted PET\u002FCT imaging in patients with confirmed or suspected Cushing's syndrome. This study will focus on evaluating the capability of \\^68Ga-Pentixafor PET\u002FCT to assist in the differential diagnosis of ACTH-dependent and ACTH-independent subtypes, as well as in the localization of primary lesions in challenging cases. Imaging performance will be assessed in comparison with conventional modalities and\u002For 68Ga-DOTATATE PET\u002FCT when available.",[29],[62,63,64,29],"pentixafor","CXCR4","PET\u002FCT","2026-01-09",{"date":67,"type":37},"2026-01-20",{"date":69,"type":37},"2023-06-12",{"date":71,"type":21},"2027-02-12",{"name":73,"class":74},"Peking Union Medical College Hospital","OTHER"]